Hero image with Pittsburgh background pittplusme.org/study/1808

STUDY BASICS

Are you the parent of a child aged 12-17 who has moderate to severe chronic plaque psoriasis? Your child may be able to participate in a study to explore a potential treatment, known as certolizumab pegol (CZP), to see if it can reduce psoriasis symptoms. Participation will last just over 3 years and involves multiple study visits. Compensation is provided.


IRB:
  SSU00111300A - UCB Biopharma SPRL - PS0007, Multicenter, randomized, parallel-group, double-blind, placebo-controlled (12-17 years) including a single open label arm (6-11 years) study to evaluate the efficacy, safety, and pharmacokinetics of certolizumab pegol (CZP) in pediatric study participants with moderate to severe chronic plaque psoriasis (PSO) (Pro00039096)

RESEARCH AREAS:
  Featured Pediatric Research

Age Range
AGE:   12-17

Duration DURATION:  Just over 3 years
VISITS:  Multiple

Location LOCATION: 
Falk Medical Building – Oakland (some visits can be completed at home)
Compensation COMPENSATION: 
Yes
Phone Number PHONE NUMBER:
1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1808
OR
Phone Number PHONE NUMBER:
1-866-438-8230

MEET THE RESEARCHER


Laura Ferris

Laura Korb Ferris, MD, PhD, is Associate Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.




PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet